ABSTRACT
Introduction Since the mid-1980s, surgery and radiotherapy have been the treatment modalities most frequently used to treat patients with prostate cancer. However, it is important to recognize the prominence brachytherapy treatments have achieved. To this respect, The American Urologic Society,1 and the American College of Radiology2
patterns of care of utilization have reported the significant increase of utilization of brachytherapy during the last decade. We will limit the extent of our data analysis and comments to a type of brachytherapy called high dose rate (HDR) brachytherapy, whether used as a monotherapy or as a boost therapy combined with pelvic external beam with or without androgen deprivation therapy (ADT).
